Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Nammi Therapeutics Inc
Jazz Pharmaceuticals
Zumutor Biologics Inc.
Astellas Pharma Inc
National Cancer Institute (NCI)
SystImmune Inc.
Merck Sharp & Dohme LLC
Mayo Clinic
Genmab
Myeloid Therapeutics
Avacta Life Sciences Ltd
Ocellaris Pharma, Inc.
Innate Pharma
Dren Bio
Mayo Clinic
Tanabe Pharma America, Inc.
Massive Bio, Inc.
ITM Oncologics GmbH
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
NuCana plc
University of Virginia
NextPoint Therapeutics, Inc.
Affiliated Hospital of Jiangnan University
Affiliated Hospital of Jiangnan University
UNICANCER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OncoC4, Inc.
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
Orion Biotechnology Polska Sp. z o.o.
SOLTI Breast Cancer Research Group
Cofactor Genomics, Inc.
Daiichi Sankyo
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Salubris Biotherapeutics Inc
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xencor, Inc.
Pliant Therapeutics, Inc.
European Institute of Oncology